• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝脏胆固醇转运及其在非酒精性脂肪性肝病和动脉粥样硬化中的作用。

Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis.

机构信息

Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang Medical College, University of South China, Hengyang, Hunan 421001, China.

Institute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan 460106, China.

出版信息

Prog Lipid Res. 2021 Jul;83:101109. doi: 10.1016/j.plipres.2021.101109. Epub 2021 Jun 11.

DOI:10.1016/j.plipres.2021.101109
PMID:34097928
Abstract

Non-alcoholic fatty liver disease (NAFLD) is a quickly emerging global health problem representing the most common chronic liver disease in the world. Atherosclerotic cardiovascular disease represents the leading cause of mortality in NAFLD patients. Cholesterol metabolism has a crucial role in the pathogenesis of both NAFLD and atherosclerosis. The liver is the major organ for cholesterol metabolism. Abnormal hepatic cholesterol metabolism not only leads to NAFLD but also drives the development of atherosclerotic dyslipidemia. The cholesterol level in hepatocytes reflects the dynamic balance between endogenous synthesis, uptake, esterification, and export, a process in which cholesterol is converted to neutral cholesteryl esters either for storage in cytosolic lipid droplets or for secretion as a major constituent of plasma lipoproteins, including very-low-density lipoproteins, chylomicrons, high-density lipoproteins, and low-density lipoproteins. In this review, we describe decades of research aimed at identifying key molecules and cellular players involved in each main aspect of hepatic cholesterol metabolism. Furthermore, we summarize the recent advances regarding the biological processes of hepatic cholesterol transport and its role in NAFLD and atherosclerosis.

摘要

非酒精性脂肪性肝病(NAFLD)是一个迅速崛起的全球健康问题,是目前世界上最常见的慢性肝脏疾病。动脉粥样硬化性心血管疾病是 NAFLD 患者死亡的主要原因。胆固醇代谢在 NAFLD 和动脉粥样硬化的发病机制中起着至关重要的作用。肝脏是胆固醇代谢的主要器官。肝脏胆固醇代谢异常不仅导致 NAFLD,还促使动脉粥样硬化性血脂异常的发展。肝细胞中的胆固醇水平反映了内源性合成、摄取、酯化和输出之间的动态平衡,胆固醇在这个过程中被转化为中性胆固醇酯,用于储存于胞质脂滴中或作为血浆脂蛋白的主要成分(包括极低密度脂蛋白、乳糜微粒、高密度脂蛋白和低密度脂蛋白)分泌出去。在这篇综述中,我们描述了几十年来的研究,旨在确定参与肝脏胆固醇代谢各个主要方面的关键分子和细胞参与者。此外,我们总结了关于肝脏胆固醇转运的生物学过程及其在 NAFLD 和动脉粥样硬化中的作用的最新进展。

相似文献

1
Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis.肝脏胆固醇转运及其在非酒精性脂肪性肝病和动脉粥样硬化中的作用。
Prog Lipid Res. 2021 Jul;83:101109. doi: 10.1016/j.plipres.2021.101109. Epub 2021 Jun 11.
2
Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.脂蛋白代谢、血脂异常与非酒精性脂肪性肝病。
Semin Liver Dis. 2013 Nov;33(4):380-8. doi: 10.1055/s-0033-1358519. Epub 2013 Nov 12.
3
Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development.雌激素相关受体α依赖性肝 VLDL 分泌功能障碍导致 NAFLD/NASH 发展的性别差异。
Theranostics. 2020 Aug 29;10(24):10874-10891. doi: 10.7150/thno.47037. eCollection 2020.
4
Resistance to Cholesterol Gallstone Disease: Hepatic Cholesterol Metabolism.对胆固醇结石病的抵抗力:肝脏胆固醇代谢
J Clin Endocrinol Metab. 2024 Mar 15;109(4):912-923. doi: 10.1210/clinem/dgad528.
5
Sterol carrier protein 2 in lipid metabolism and non-alcoholic fatty liver disease: Pathophysiology, molecular biology, and potential clinical implications.固醇载体蛋白 2 在脂质代谢和非酒精性脂肪性肝病中的作用:病理生理学、分子生物学及潜在的临床意义。
Metabolism. 2022 Jun;131:155180. doi: 10.1016/j.metabol.2022.155180. Epub 2022 Mar 17.
6
Interpreting lipoproteins in nonalcoholic fatty liver disease.解读非酒精性脂肪性肝病中的脂蛋白
Curr Opin Lipidol. 2017 Aug;28(4):355-360. doi: 10.1097/MOL.0000000000000427.
7
Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD).内溶酶体网络在胆固醇稳态和代谢相关脂肪性肝病(MAFLD)中的功能。
Mol Metab. 2021 Aug;50:101146. doi: 10.1016/j.molmet.2020.101146. Epub 2021 Jan 5.
8
Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.非酒精性脂肪性肝病的严重程度及进展为肝硬化与致动脉粥样硬化脂蛋白谱相关。
Clin Gastroenterol Hepatol. 2015 May;13(5):1000-8.e3. doi: 10.1016/j.cgh.2014.10.008. Epub 2014 Oct 13.
9
Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases.线粒体脂质稳态在肝脏和心脏疾病的交汇点。
Int J Mol Sci. 2021 Jun 28;22(13):6949. doi: 10.3390/ijms22136949.
10
Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).非酒精性脂肪性肝病 (NAFLD) 中维生素 A 代谢紊乱。
Nutrients. 2017 Dec 29;10(1):29. doi: 10.3390/nu10010029.

引用本文的文献

1
Exploring the biological functions and immune regulatory roles of IRAK3, TNFRSF1A, CX3CR1, and JUNB in T2DM combined with MAFLD: integrated bioinformatics and single-cell analysis.探索IRAK3、TNFRSF1A、CX3CR1和JUNB在2型糖尿病合并代谢相关脂肪性肝病中的生物学功能及免疫调节作用:综合生物信息学与单细胞分析
Front Immunol. 2025 Aug 22;16:1587225. doi: 10.3389/fimmu.2025.1587225. eCollection 2025.
2
Regulatory mechanisms of hepatocyte PCSK9 expression: translating mechanistic insights into potential nutraceuticals.肝细胞中前蛋白转化酶枯草溶菌素9(PCSK9)表达的调控机制:将机制性见解转化为潜在的营养保健品
Chin Med. 2025 Aug 5;20(1):121. doi: 10.1186/s13020-025-01178-y.
3
Pitavastatin-loaded procyanidins self-assembled nanoparticles alleviate advanced atherosclerosis modulating macrophage efferocytosis and cholesterol efflux.
载有匹伐他汀的原花青素自组装纳米颗粒通过调节巨噬细胞胞葬作用和胆固醇流出减轻晚期动脉粥样硬化。
Acta Pharm Sin B. 2025 Jun;15(6):3305-3320. doi: 10.1016/j.apsb.2024.08.006. Epub 2025 May 6.
4
Nano-Encapsulated Phytosterols Ameliorate Hypercholesterolemia in Mice via Dual Modulation of Cholesterol Metabolism Pathways.纳米包裹植物甾醇通过对胆固醇代谢途径的双重调节改善小鼠高胆固醇血症
Nutrients. 2025 Jun 23;17(13):2086. doi: 10.3390/nu17132086.
5
Integrative analysis of cholesterol homeostasis reveals prognostic subtypes and immune features in clear cell renal cell carcinoma.胆固醇稳态的综合分析揭示了透明细胞肾细胞癌的预后亚型和免疫特征。
Discov Oncol. 2025 Jul 4;16(1):1261. doi: 10.1007/s12672-025-03116-8.
6
Combination Therapy of Half-Dose Resmetirom and Metformin Attenuates Metabolic Dysfunction-Associated Steatohepatitis Through Improving Cholesterol Metabolism and Inflammation.半剂量瑞美鲁肽与二甲双胍联合治疗通过改善胆固醇代谢和炎症减轻代谢功能障碍相关脂肪性肝炎
Biomedicines. 2025 May 27;13(6):1315. doi: 10.3390/biomedicines13061315.
7
Anti-atherosclerotic effects and molecular targets of salvianolic acids from Bunge.来自 Bunge 的丹酚酸的抗动脉粥样硬化作用及分子靶点。
Front Pharmacol. 2025 May 21;16:1574086. doi: 10.3389/fphar.2025.1574086. eCollection 2025.
8
Biomimetic nanocomplexes loading with evolocumab and curcumin for synergistic anti-atherosclerosis therapy in ApoE mice.负载依洛尤单抗和姜黄素的仿生纳米复合物用于ApoE小鼠的协同抗动脉粥样硬化治疗
J Nanobiotechnology. 2025 Jun 3;23(1):412. doi: 10.1186/s12951-025-03444-5.
9
Allantoin Serves as a Novel Risk Factor for the Progression of MASLD.尿囊素是MAFLD进展的一种新的危险因素。
Antioxidants (Basel). 2025 Apr 22;14(5):500. doi: 10.3390/antiox14050500.
10
Association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): data from the NHANES III (1988-1994).非高密度脂蛋白胆固醇与高密度脂蛋白胆固醇比值(NHHR)与代谢功能障碍相关脂肪性肝病(MASLD)患者死亡率之间的关联:来自美国国家健康和营养检查调查III(1988 - 1994)的数据
Nutr Metab (Lond). 2025 May 21;22(1):46. doi: 10.1186/s12986-025-00942-z.